The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese

Atherosclerosis

Volumn 136, Issue 2, 1998, Pages 217-223

  Sanghera, Dharambir K ^a   Saha, Nilmani ^a   Kamboh, M Ilyas ^a  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Asian Indians; CHD risk; Chinese; Genetic polymorphisms; Paraoxonase

Indexed keywords

ARYLESTERASE;

ADULT; AGED; ARTICLE; ASIAN; CHINESE; CODON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ETHNIC GROUP; FEMALE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLDIALKYLPHOSPHATASE; CHINA; CODON; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; ESTERASES; FEMALE; HAPLOTYPES; HUMANS; INDIA; LINKAGE DISEQUILIBRIUM; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0032006253     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00206-2     Document Type: Article

References (34)

1. Breslow J.L. Apolipoprotein genetic variation and human disease. Physiol Rev. 68:1988;85-132.
2. Humphries S.E. DNA polymorphisms of the apolipoprotein gene: their use in investigating the genetic component of hyperlipidemia and atherosclerosis. Atherosclerosis. 72:1988;89-108.
3. Sing C.F., Moll P.P. Genetics of atherosclerosis. Ann Rev Genet. 24:1990;171-187.
4. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135.
5. Watson A.D., Navab M., Hama S.Y.et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 95:1995;774-782.
6. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmaco Genetics of Drug Metabolism. New York: Pergamon, 1992:51-91.
7. Blatter Garin M.-C., James R.W., Messmer S., Barja F., Pometta D. Identification of high density lipoprotein subspecies defined by a lipoprotein-associated protein, k-45. Eur J Biochem. 211:1993;871-879.
8. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony A.K. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;832-839.
9. Navab M., Berliner J.A., Watson A.D.et al. The yin and yang of the oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol. 16:1996;831-842.
10. Mackness M.I., Durrington P.N. HDL, its enzymes and and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
11. Watson A.D., Berlinor J.A., Hama S.Y.et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 96:1995;2882-2891.
12. Simeon V., Pavkovic E. Heat inactivation of paraoxonase and arylesterase activities in human and rabbit serum. Chem-Biol Interact. 87:1993;103-107.
13. Diepgen T.L., Geldmacher-vonMallinckrodt M. Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol. Suppl 9:1986;154-158.
14. Roy A.C., Saha N., Tay J.S.H., Ratnam S.S. Serum paraoxonase polymorphism in three populations of Southeast Asia. Hum Hered. 141:1991;265-269.
15. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 52:1993;598-608.
16. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 3:1993;73-76.
17. Davies H.G., Rebecca J.R., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and serin. Nat Genet. 4:1996;334-336.
18. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33:1996;498-507.
19. Mackness M.I., Harty D., Bhatnagar D.et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:1991;193-199.
20. Nishigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med. 25:1981;373-378.
21. Mackness M.I., Walker C.H., Carlson L.A. Low 'A'-esterase activity in serum of patients with fish-eye disease. Clin Chem. 3:1987;587-588.
22. Mackness M.I., Peuchant E., Dumon M.-F., Walker C.H., Clerc M. Absence of 'A'-esterase activity in serum of patients with Tangier disease. Clin Biochem. 22:1989;475-478.
23. Abbot C.A., Mackness M.I., Kumar S., Boulton A., Durrington P.N. Activity, concentration and phenotype distribution in diabetic mellitus serum paraoxonase and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 15:1995;1812-1818.
24. Ruiz J.H., Blanche R.W., James M.-C.et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
25. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 96:1995;3005-3008.
26. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymophism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 17:1997;1067-1073.
27. Antikainen M., Murtomaki S., Syvanne M.et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of the coronary artery disease in Finns. J Clin Invest. 98:1996;883-885.
28. Herrmann S.-M., Blanc H., Poirier O.et al. The Gln/Arg polymorphism of the human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126:1996;299-303.
29. Blatter Garin M.-C., James R.W., Dussoix P.et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme: a possible link between paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 99:1997;62-66.
30. Saha N., Liu Y., Low P.S., Tay J.S.H. Association of factor VII genotypes with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. Arterioscler Thromb. 14:1994;1923-1927.
31. Friedewald W.T., Levi R.I., Fredrickson D.S. Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrifuge. Clin Chem. 8:1972;499-502.
32. Parzer S., Mannhalter C.A. Rapid method for the isolation of genomic DNA from citrate whole blood. Biochem J. 273:1991;229-231.
33. Kanji GK. 100 Statistical Tests. Newbury Park, CA: Sage Publications, 1993.
34. Kamboh M.I., Hamman R.F., Ferrell R.E. Two polymorphisms in the APO A-IV coding gene: their evolution and linkage disequilibrium. Genet Epidemiol. 9:1992;305-315.